METHODS: A retrospective analysis of 3324 stage II/III CRC patients aged < 70 years was conducted, focusing on age-based subgroups (< 50 vs. ≥ 50 years). Propensity score matching balanced clinical characteristics. Relapse-free survival (RFS) and overall survival (OS) were analyzed.
RESULTS: In stage II CRC, age of onset did not impact prognosis after adjuvant chemotherapy, with no significant differences in RFS (5-year RFS rates: 80% in both groups, p = 0.98) and OS (5-year OS rates: 96% vs. 92%, p = 0.17). In stage III, a trend suggested slightly poorer OS in patients aged < 50 years than those ≥ 50 years (5-year OS rates: 85% vs. 88%, p = 0.077). However, in a propensity score-matched cohort, age-dependent differences were attenuated (5-year OS rates: 85% vs. 88%, p = 0.32).
CONCLUSIONS: In the context of stage II/III CRC patients receiving adjuvant chemotherapy, age was not an independent predictor of prognosis. Age alone should not be the sole factor guiding treatment decisions.
方法:对3324例年龄<70岁的II/III期CRC患者进行回顾性分析,侧重于基于年龄的亚组(<50vs.≥50年)。倾向评分匹配平衡的临床特征。分析无复发生存期(RFS)和总生存期(OS)。
结果:在第二阶段CRC中,发病年龄不影响辅助化疗后的预后,RFS无显著差异(5年RFS率:两组均为80%,p=0.98)和OS(5年OS率:96%与92%,p=0.17)。在第三阶段,趋势表明,年龄<50岁的患者的OS比年龄≥50岁的患者稍差(5年OS率:85%vs.88%,p=0.077)。然而,在倾向得分匹配的队列中,年龄依赖性差异减弱(5年OS率:85%vs.88%,p=0.32)。
结论:在II/III期CRC患者接受辅助化疗的情况下,年龄不是预后的独立预测因子.仅年龄不应成为指导治疗决定的唯一因素。